<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114304</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210292</org_study_id>
    <nct_id>NCT05114304</nct_id>
  </id_info>
  <brief_title>Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis</brief_title>
  <acronym>PsyHistio</acronym>
  <official_title>Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis: an Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that&#xD;
      occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of&#xD;
      anxiety symptoms and an addictive profile. However, no study to date has precisely&#xD;
      investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of&#xD;
      the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH&#xD;
      patients.&#xD;
&#xD;
      This study should allow:&#xD;
&#xD;
        -  to assess the prevalence of psychiatric disorders co-morbid in PLCH patients&#xD;
&#xD;
        -  a targeted and more effective management of patients&#xD;
&#xD;
        -  a better response rate to smoking and cannabis weaning, that represents a major goal for&#xD;
           these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test</measure>
    <time_frame>at inclusion</time_frame>
    <description>The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least one comorbid addictive disorder among: tobacco, alcohol, cannabis, benzodiazepines, cocaine, opiates</measure>
    <time_frame>at inclusion</time_frame>
    <description>Definition and diagnosis of addictive disorder will be assessed with Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with active tobacco consumption with or without comorbid psychiatric disorder</measure>
    <time_frame>at inclusion</time_frame>
    <description>Tobacco consumption will be assessed by Fagerström survey and DSM-5, cotinine in urine quantification and expired carbon monoxide for patients using nicotine substitutes. Fargerstrom test evaluates the dependence on cigarettes from 0 to 10 (0 indicated a very low dependence and 10 a very strong dependence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with persistent tobacco consumption despite nicotine replacement treatment</measure>
    <time_frame>at inclusion</time_frame>
    <description>Tobacco consumption will be assessed by Fagerström survey and DSM-5 and expired carbon monoxide for patients with nicotine substitutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of previous tobacco weaning episodes and co-morbid psychiatric disorders</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of co-morbid psychiatric disorders</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with psychiatric disorders as assessed by Mini International Neuropsychiatric Interview (MINI) test</measure>
    <time_frame>at inclusion</time_frame>
    <description>The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Langerhans Cell Histiocytosis</condition>
  <arm_group>
    <arm_group_label>Pulmonary Langerhans cell histiocytosis (PLCH)</arm_group_label>
    <description>Adults with pulmonary Langerhans cell histiocytosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of co-morbid psychiatric disorders</intervention_name>
    <description>Added scales :&#xD;
Mini Internationnal Neuropsychiatric Interview&#xD;
Fagerström test&#xD;
DSM-5 Scale&#xD;
Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics&#xD;
Expired carbon monoxide for patients using nicotine substitutes</description>
    <arm_group_label>Pulmonary Langerhans cell histiocytosis (PLCH)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with pulmonary Langerhans cell histiocytosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of 18 years of age or older with PLCH diagnosed at adulthood&#xD;
&#xD;
          -  Patients affiliated to the French Health Care System&#xD;
&#xD;
          -  Informed patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to understand the interview (language barrier)&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient under AME (French medical help for foreigners)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdellatif TAZI</last_name>
    <phone>+33142499618</phone>
    <email>abdellatif.tazi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Resche-Rigon, Pr</last_name>
    <phone>+33142499742</phone>
    <email>matthieu.resche-rigon@u-paris.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Saint-Louis, Centre de référence national des histiocytoses, Service de Pneumologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Abdellatif TAZI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

